Overview
Comprehensive genomic profiling (CGP) assay for advanced solid tumors that interrogates >500 cancer-associated genes and multiple biomarker classes from a single FFPE specimen.
Why this Test Matters
Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.
Who Should Consider this Test?
● Advanced/metastatic solid tumors ● Relapsed or refractory disease ● Rare cancers ● Patients being evaluated for targeted therapy, immunotherapy or clinical trials
Applicable Cancer Types
Lung, Breast, Colorectal, Ovarian, Prostate, Gastric, Pancreatic, Melanoma, Endometrial, Head & Neck, Brain, Sarcoma, Other solid tumors
What is Covered?
- 500+ genes
- SNVs
- InDels
- CNVs
- BRCA1/2 rearrangements
- Gene fusions
- MSI
- TMB
- LOH
Clinical Utility
- Treatment selection Prognostic and predictive biomarkers
- Clinical trial matching
- Identification of actionable
- Alterations Comprehensive
- Clinical interpretation
Technology
Comprehensive DNA and fusion profiling using high-depth NGSkey Features
| Parameter | Details |
|---|---|
|
Sample Type |
FFPE tissue |
|
Samples |
1 FFPE block or 10–15 slides |
|
Turnaround Time |
14–21 working days |
|
Report Includes |
Variant interpretation, therapy associations, clinically actionable biomarkers |
|
Quality |
High-depth NGS with rigorous QC |